FDA: The outlook for 2022

By Dr Nicola Davies

Since 2020, the US Food and Drug Administration’s activities have centered around the response to the COVID-19 pandemic.1

The agency closed out 2021 with the approval of two oral antivirals for COVID-19 - Pfizer’s (NYSE: PFE) Paxlovid co-packaged nirmatrelvir and ritonavir tablets and Merck & Co’s (NYSE: MRK) Lagevrio (molnupiravir).2,3 Nevertheless, in addition to these activities, the agency has been working on various non-pandemic-related initiatives. Here, we look at some of the FDA’s planned activities for 2022.